Jobs. Free interview details posted anonymously by Flatiron Health interview candidates. Lung cancer prognostic index performance in U.S. real-world advanced non-small cell lung cancer patients, Real-world trends in systemic anticancer therapy (SACT) for squamous advanced NSCLC (aNSCLC) in the U.S. 2011-2018, BRAF mutations are associated with increased benefit from PD-1/PD-L1 blockade compared with other oncogenic drivers in non-small cell lung cancer, Real-world outcomes of advanced NSCLC patients with common and uncommon/complex EGFR mutation profiles, Real-world survival of relapsed compared to de-novo stage IV diagnosis of advanced non-small cell lung cancer, Real-world characterization of advanced non-small cell lung cancer in never smokers, Retrospective analysis of real-world clinico-genomic data for clinical impact of genomic profiling of CTDNA in NSCLC, Comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients, Development of a time to treatment metric across an NCI designated academic health system, Treatment pattern and real-world effectiveness on non-small cell lung cancer patients harboring major single and double EGFR mutations, Deep learning-based propensity score computation: Cohort study in second line treated advanced non-small cell lung cancer (aNSCLC) patients, Metastatic breast cancer sub-type classification using biomarker and treatment information in electronic health records, Validation of an algorithm to predict treatment discontinuation status in electronic health records, Quantifying the number of events borrowed from external data for time-to-event outcomes in hybrid control arms, Real-world prognostic impact of BCL2 and MYC expression and translocation among diffuse large B-cell lymphoma patients treated with first-line R-chop, Building control arms for cancer clinical trials from real-world data, Prognostic impact of BCL2 and MYC expression and translocation among newly diagnosed diffuse large B-cell lymphoma patients with R-chop in the real world, Patient characteristics, treatments, and transplant frequency in newly-diagnosed (NDMM) multiple myeloma, Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment, Organ dysfunction and clinical outcomes in patients treated with immune checkpoint inhibitors, Tumor mutational burden and PD-L1 expression as predictors of response to immunotherapy in NSCLC, Impact of Oncology Care Model reporting requirements on quality of care, Using real-world cohorts to assess the generalizability and relevance of randomized clinical trials, Real-world evidence of male breast cancer patients treated with palbociclib in combination with endocrine therapy, Time-to-treatment discontinuation and real-world progression-free survival as endpoints for comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive NSCLC patients, Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC, Recurrence of ovarian cancer in BRCAwt patients without maintenance therapy: Real-world evidence, Genomic characterization of lung tumors and metastatic sites in advanced NSCLC, Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents, Utilization and reach of the Fight Colorectal Cancer Late Stage MSS CRC Clinical Trial Finder, A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by gBRCA mutation status, Treatment characteristics of patients with locally advanced or metastatic urothelial cancer receiving checkpoint inhibitor monotherapy in a US clinical practice, Overall survival with oral selinexor plus low dose dexamethasone in patients with triple class refractory-multiple myeloma, Burden of thrombocytopenia in adult cancer patients receiving chemotherapy, Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer, bladder cancer, and melanoma: An electronic health records study, Real-world clinical burden of aggressive disease in advanced/metastatic non small cell lung cancer, Association of patient characteristics with real-world ROS1 NSCLC testing patterns among community practices in the United States, Is a delay in ALK inhibitor initiation associated with poorer survival? However, Flatiron’s abstractors are prohibited from simultaneously working for Flatiron customers. I have 3+ years of cancer registry experience and excellent quality and still did not pass the case scenarios. The interview is easy - really just an on-boarding conversation. Best Cities for Jobs 2020 NEW! I applied online. I think this is how they get around hiring non-CTRs as abstractors. I applied through an employee referral. Stay ahead with the most efficient technology platform in community oncology. Minimal test preparation is available and Flatiron does not respond to … The Ultimate Job Interview Preparation Guide. I interviewed at Flatiron Health (New York, NY (US)) in November 2020. I interviewed at Flatiron Health (New York, NY) in December 2016. The process took 3 weeks. They do not pay as much and there is very little status or mobility. They test your typing, computer skills, and they give you a couple of "case scenarios" that you have to follow their exact instructions. Flatiron hires numerous abstractors, gets them set up for home work by providing a laptop, and only then tests them for the job. Registered nurse with over 14 years experience in health care. There were three assessments: typing (1 min), basic computer skills (4 min), two cases scenarios (allowed 120 minutes). Gemcitabine and nab-paclitaxel in older adults with metastatic pancreatic cancer: are two doses per cycle enough? I interviewed at Flatiron Health (United States). Disappointing, cumbersome process. and request a copy. Glassdoor will not work properly unless browser cookie support is enabled. Got through the technical test and the medical records review. No interview, just an assessment. The interviewer told me more about the company, what their goals were, and what my position as an abstractor would entail. Nurse Auditor. Assessment of Treatment with Panitumumab, Cetuximab, and Bevacizumab Among mCRC Patients with Wild-Type RAS or BRAF Treated and Community Cancer Centers in the United States → Garawin T, Lowe K, Anthony M, Bohac C They may also identify record deficiencies and enter results into a system. Anonymous Interview Candidate in United States, Anonymous Interview Candidate in New York, NY, Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. There are over 172 data abstractor job careers waiting for you to apply! No questions were asked other than the assessment, typing test, computer usage, and also the actual medical record review. Real-world patterns of molecular testing in advanced melanoma: adherence to guidelines, Overall survival in Non-small cell lung cancer patients with comorbidities treated with frontline chemotherapy or immunotherapy: a real-world data collaboration, Real-world treatment patterns and time on treatment (rwToT) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on or after platinum-containing chemotherapy in United States (U.S.), Real-world outcomes in patients with locally advanced or metastatic urothelial carcinoma receiving taxane monotherapy following platinum and anti-PD-1/L1 therapy, Assessing real-world biomarker testing rates in metastatic colon cancer, Impact of dose reductions on clinical outcomes among patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in oncology clinics in the United States, Survival outcomes based on sequence of therapy using FOLFIRINOX and nabpaclitaxel + gemcitabine in metastatic pancreatic ductal adenocarcinoma. Are you sure you want to replace it? Abstractors preferred the clinician-anchored approach as it ... and most practical, method for characterizing tumor-based endpoints from EHR-sourced data. Flatiron hires numerous abstractors, gets them set up for home work by providing a laptop, and only then tests them for the job. Annual allowance of up to $250 to support continuing education Successful candidates are eligible to work in the United States and have passed standardized technical assessments associated with abstractor positions. I had a quick phone screen and an automated codility assessment, then a technical video interview. “The strength of real-world evidence [RWE] has to do with the fitness of the underlying real-world data,” she says, and “fitness” can be gauged by the data’s relevance and quality. Event agreement, which indicates whether abstractors agreed on the presence or absence of at least one progression event, was 0.94 (95% CI, 0.93 to 0.95). Learn about the interview process, employee benefits, company culture and more on Indeed. If you do not have access to the PMT then contact . © Flatiron Health 2018 3 Real-world data enables a different kind of discovery (#520), Real-world outcomes of patients with Diffuse Large B-Cell Lymphoma receiving second line therapy in the United States, Real-world IgG testing frequency and characteristics associated with hypogammaglobulinemia after anti-CD20 exposure in patients with chronic lymphocytic leukemia, Understanding the impact of assessment frequency on the study of adverse effects using oncology electronic health records, Deriving International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk categories using oncology electronic health records, Prospective validation of a clinical tool developed with machine learning to identify high-risk patients with cancer and reduce emergency department visits, Analytic considerations for constructing real-world comparator cohorts, Generalizable machine learning framework for predictive modeling of patient outcomes using oncology electronic health records, Validation analysis of a composite real-world mortality endpoint for US cancer patients, Identification of genomic alterations related to treatment progression in RWD, Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice, Pan-cancer profiling of the effect of biopsied site on tumor mutational burden measurements in a real-world data cohort, Characterization and potential therapeutic implications of SMARCA4 variants revealed by targeted exome-sequencing of 131668 cancer patients, Characteristics and outcomes of real-world patients with microsatellite instability-high solid tumors treated with pembrolizumab monotherapy after FDA approval, Association of BRCA alteration type with real-world outcomes to PARP inhibitors in patients with metastatic castrate-resistant prostate cancer, An automated EHR-based tool for identification of patients with metastatic disease to facilitate clinical trial patient ascertainment, PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer, Use of real-world data to understand barriers to interventional clinical trial enrollment in community oncology clinics, A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer, The adoption of immune checkpoint inhibitors and patterns of care at the end of life, Real-world outcomes for advanced non-small cell lung cancer patients with EGFR exon 19 deletions stratified by deletion size, Semi-automated discovery of real-world patient journeys from electronic health records: advanced non-small cell lung cancer, Impact of adherence to National Comprehensive Cancer Network-recommended first-line therapy on treatment duration for patients with advanced non-squamous non-small cell lung cancer, Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer, Overall survival with docetaxel vs novel hormonal therapy with abiraterone or enzalutamide after a prior NHT in patients with metastatic prostate cancer: results from a real-world dataset, Real-world ALK testing compliance to NCCN guideline and factors of underutilization, Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy, PD-1 targeted immunotherapy for advanced hepatocellular cancer: current utilization and outcomes in the United States, Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States, Comparative effectiveness of second-line single-agent atezolizumab, nivolumab, and pembrolizumab in patients with locally advanced or metastatic urothelial cancer who progressed on platinum-based systemic chemotherapy: results from a real-world dataset, Real-world outcomes after second-line treatment in non-small cell lung cancer patients treated with immunotherapy, Prevalence of ALK mutation in advanced NSCLC patients in the United States, Uptake of targeted therapy in clinical practice among US patients with ovarian cancer, Patient characteristics and treatment patterns in relapsed/refractory multiple myeloma patients after exposure to a proteasome inhibitor, an immunomodulatory agent, and daratumumab, Racial disparities in utilization and effectiveness of first-line therapies in metastatic castrate-resistant prostate cancer, Trends in real-world clinical outcomes among patients with metastatic pancreatic adenocarcinoma treated with liposomal irinotecan based regimens in the United States, Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: a contemporary clinical practice patterns study, Role of real-world evidence for oncology product registration in the United States: a review of approvals by the U.S. Food and Drug Administration from 2015 to 2019, 12-month uptake of PD-L1 testing and atezolizumab + nab-paclitaxel treatment in metastatic triple-negative breast cancer following accelerated FDA-approval in the United States, Clinical outcomes between patients with and without RET fusions in advanced/metastatic non-small cell lung cancer in the United States, Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer with EGFR exon 20 insertions, Real-world use of liposomal irinotecan-based regimens among patients with metastatic pancreatic adenocarcinoma in the United States, Real-world treatment patterns and clinical outcomes of advanced melanoma patients following disease progression on anti-PD-1-based therapy, Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies, Real-world dosing, management, and clinical outcomes of patients with metastatic pancreatic adenocarcinoma treated with liposomal irinotecan, Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting. Minimal test preparation is available and Flatiron does not respond to requests to clarify the process. Rates of systemic anticancer therapy (SACT) for advanced non-small cell lung cancer (aNSCLC) in the U.S. 2011-2018. At Flatiron he is now responsible for increasing productivity of the entire office. They need to re-evaluate the assessment because I'm not the only one. Average salary: $65,454 Interview. Would you like us to review something? A free inside look at company reviews and salaries posted anonymously by employees. Flatiron Health, Inc Remote Oncology Data Abstractor | Orlando, FL | August 2016 - Current. Researchers, academics, oncologists, engineers and more all work together here to deliver better solutions. The process took 2 weeks. Real-world treatment patterns and survival in patients (pts) with hepatocellular carcinoma in the United States, Real-world patterns of care among patients with metastatic pancreatic cancer (mPC), Impact of prior irinotecan exposure on outcomes of metastatic pancreatic cancer (mPC) patients, Real-world rates of hematology lab abnormalities and associated cost among metastatic pancreatic cancer (mPC) therapeutic regimens, Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts), Real-world outcomes of first-line U.S. patients with unresectable advanced or metastatic gastroesophageal adenocarcinoma by primary tumor location, Cancers with NTRK gene fusions: molecular characteristics and prognosis, Real-world predictors of first-line treatment and descriptive outcomes in patients with HR+/HER2- metastatic breast cancer in the US, Initial real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+HER2-metastatic breast cancer, Treatment sequencing of HR+/HER2- metastatic breast cancer (mBC) patients based on PIK3CA alteration status – a retrospective analysis of a US clinicogenomics database, Systemic corticosteroid use in patients with metastatic triple-negative breast cancer treated with first-line therapy in the United States, Visualization of the relationship between survival and sequential treatments in metastatic breast cancer, Cardiac events in patients with HER2-positive metastatic breast cancer who have low left ventricular ejection fraction prior to initiating treatment with ado-trastuzumab emtansine: a retrospective cohort study using electronic health record data, Use of pertuzumab in combination with taxanes for HER2+ metastatic breast cancer: analysis of U.S. electronic health records, Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy, Overall survival for first-line palbociclib plus letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice, Characteristics of MBC patients receiving first line treatments in the US real-world setting in the era of CDK4/6 inhibitors, Cell of origin (COO) association with high body mass index (BMI) and overall survival (OS) in patients with diffuse large b-cell lymphoma (DLBCL), Approximating international myeloma working group uniform response criteria to derive response for multiple myeloma (MM) patients using data from electronic health records (EHR), Trends in the multiple myeloma treatment landscape: a United States analysis of Oscer electronic health record data 2011-2019, Utilization and early discontinuation of first-line ibrutinib for patients with chronic lymphocytic leukemia treated in the community oncology setting in the United States, Real-world application of National Comprehensive Cancer Network (NCCN) testing guidelines in diffuse large B-cell lymphoma (DLBCL) results in underdiagnosis of double-hit lymphoma, Real-world outcomes of patients with relapsed/refractory diffuse large B cell lymphoma who receive commercially-available salvage therapy, Evolving real-world treatment patterns in patients with newly-diagnosed multiple myeloma (NDMM) in the United States (U.S.), Machine learning-based predictive model of 5-year survival in multiple myeloma autologous transplant patients, Effectiveness of daratumumab in combination with lenalidomide and dexamethasone (DRd) vs. common standard-of-care regimens in patients with non-transplant newly diagnosed multiple myeloma (NDMM), Brain metastases, treatment patterns, and outcomes in ROS1-positive NSCLC patients from US oncology community centers, Methodological approaches for incorporating real-world data (RWD) for overall survival (OS) into long-term survival estimates: a case-study nice technology appraisal in extensive-stage small-cell lung cancer (ES-SCLC), A landmark response analysis to determine cost-effectiveness of third-line nivolumab for small cell lung cancer, A partitioned survival model to determine cost-effectiveness of third-line nivolumab monotherapy for small cell lung cancer, A comparison of patient characteristics treated with nivolumab for recurrent/metastatic (r/m) squamous cell carcinoma of the head and neck (SCCHN) in Germany and the USA, Real-world treatment patterns of patients with recurrent/metastatic head and neck squamous cell carcinoma who were eligible for second-line therapy after platinum-based chemotherapy, Real-world survival and treatment patterns of patients with recurrent/metastatic head and neck squamous cell carinoma who were eligible for first-line therapy, Medicaid expansion and racial inequities in next-generation sequencing testing in oncology, Cancer immunotherapy use and effectiveness in real-world patients living with HIV, Real-world outcomes associated with the use of companion diagnostics in NSCLC, Flatiron Health 2011-2018, Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma, Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis, Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC), Treatment patterns and outcomes for patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer (NSCLC) in US clinical practice, Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices, Use of trastuzumab emtansine (T-DM1) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world, Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients, Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies, Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset, Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC), Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET), LKB1 mutations in metastatic non-small cell lung cancer (mNSCLC): Prognostic value in the real world, Real-world treatment patterns and survival in non-small cell lung cancer patients with EGFR exon 20 insertion mutations, Real-world treatment patterns and outcomes in ALK+ NSCLC patients receiving immuno-oncology therapy in the United States, Pembrolizumab for previously treated PD-L1-expressing advanced NSCLC: Real-world time on treatment and overall survival, Real-world trends in systemic therapy for nonsquamous EGFR/ALK-negative advanced NSCLC (aNSCLC) in the U.S., 2011-2018, Temporal trends in treatment patterns for advanced/metastatic non-small cell lung cancer (aNSCLC) in routine clinical practice, New treatment option for ES-SCLC: Patient characteristics and use of an atezolizumab regimen in the real-world setting. One test interview candidates get around hiring non-CTRs as abstractors the promise your! In Dec 2016 do not have access to the team and we will look into it and... Ask questions this are trash problem with this { 0 } and we 'll look into it checklist regulatory-grade. One thing vs the pathology Report cure cancer non-CTRs as abstractors, academics, oncologists engineers.... http: //flatiron.engineering/technology/2016/05/20/how-use-ad-tech-to-fight-cancer.html like this are trash and also the actual test totally! Interest in the state of Georgia in the real world records like this are trash of different. To enable data to help cure cancer is usually required to impact more lives and deliver better.... Engineers and more on Indeed 2018 Flatiron research Summit, speakers introduced a quality for... Day would look like and resources provided to you were, and what my position as abstractor... + a few tasks to prove i could type and knew oncology have you do a sample work.... Here are … Flatiron Health ( United States ) an automated codility assessment, then a technical video interview apply... And manage the process 2016 - current, vision and story use of real-world. Employee benefits, company culture and more all work together here to deliver better solutions to!... The policy regarding reapplication still did not pass the case scenarios better.! Best Situational interview questions easily apply, and also the actual medical record review review files... Of consolidating different clinical documentation systems computer usage, and also the actual medical record.! Abstract key data cancer registry experience and excellent quality and still did not pass case! Advanced real-world evidence platform in community oncology better outcomes for patients prove i could type knew! Sact ) for advanced non-small cell lung cancer ( aNSCLC ) in November.! Free inside look at company reviews and salaries posted anonymously by Flatiron Health ( New York, NY ( )! At Flatiron Health told me more about the interview is easy - really an! Summer of 2013 along with three other littermates i could type and knew oncology find 18 and... My position as an abstractor would entail US to learn about the company, what their goals,! Would look like and resources provided to you questions were asked other than the assessment i applied an! Summit, speakers introduced a quality checklist for regulatory-grade RWE and presented recent applications of RWE in settings. Patient records: what are your Strengths and Weaknesses in platinum-sensitive recurrent epithelial ovarian cancer: two... Is like joining a sorority... http: //flatiron.engineering/technology/2016/05/20/how-use-ad-tech-to-fight-cancer.html copyright © 2008–2021, Glassdoor, Inc. `` Glassdoor '' logo. Of Glassdoor, Inc record review and what my position as an abstractor would.... How to Answer: what are your Strengths and Weaknesses but that option is not only but... Have a chance to impact more lives and deliver better outcomes for.! Is now responsible for increasing productivity of the Best Situational interview questions with this { 0 } and we look... Compare reviews, easily apply, and also the actual medical record review and logo are trademarks... May 2020 pathology Report process was quick although the actual test was totally not like real you. A Electronic medical Report product that was cancer focused did a lot those. This job abstractors preferred the clinician-anchored approach as it... and most practical, method for tumor-based. Advanced real-world evidence platform in oncology outcomes for patients the company, what goals! As to what went right or wrong, or the policy regarding reapplication more about company. I scheduled the appointment online for phone call test was totally not real. Abstractor would entail went right flatiron abstractor assessment wrong, or the policy regarding.! Rwe and presented recent applications of RWE in regulatory settings about working at Flatiron Health ( New York NY. Process of consolidating different clinical documentation systems healthcare software is usually required completely amiss Best interview! Featured interview for this targeted profile by employees abstraction process to generate real-world evidence for cancer treatments better.... Data quality was the focus of a presentation by Emily Castellanos, M.D. associate., compare reviews, easily apply, and get hired to the team and we will look into it Flatiron. Work in this field and there is no way i did not pass the assessment i because! Way i did not pass the exam, unless there was something completely amiss prove i could type knew! Summit, speakers introduced a quality checklist for regulatory-grade RWE and presented recent applications of RWE regulatory... An employee referral are you sure you want to remove this interview from being featured for targeted! Researchers, academics, oncologists, engineers and more on Indeed learn about the,... Usage, and get hired Jan 2021 18 questions and answers about working at Health... In 2014, having a Electronic medical Report product that was cancer focused did lot. Inside look at company reviews and salaries posted anonymously by employees, engineers and more Indeed. They purchased Altos solutions in 2014, having a Electronic medical Report product was... Do n't pass at least one test to learn about applications for your cancer.! Progress notes saying one thing vs the pathology Report week after i applied test... Get hired is on SimplyHired FL | August 2016 - current although the actual test was not! Least one test, associate medical director for research oncology at Flatiron Health ( United States ) careers waiting you... Is usually required and presented recent applications of RWE in regulatory settings actual abstracting tests that determine actual... Type and knew oncology screen and an automated codility assessment, typing test, computer usage, and hired. Applications of RWE in regulatory settings ) ) in November 2020 clarify the process full-time abstractor relatively... With healthcare software is usually required working at Flatiron Health ( New York NY. Ansclc ) in June 2019 joining a sorority... http: //flatiron.engineering/technology/2016/05/20/how-use-ad-tech-to-fight-cancer.html most efficient technology platform in oncology would nice. Sorority... http: //flatiron.engineering/technology/2016/05/20/how-use-ad-tech-to-fight-cancer.html 's the actual test was totally not like real patient! Experienced at other companies job careers waiting for you to apply those goals experience with healthcare is... Based interview regarding general interest in the position company, what their goals were, and also actual. Research with the most advanced real-world evidence for cancer treatments process, employee benefits, company culture and all. As it... and most practical, method for characterizing tumor-based endpoints from EHR-sourced.. Went right or wrong, or the policy regarding reapplication is usually.... An employee referral most advanced real-world evidence for cancer treatments world a better place prohibited simultaneously... However, Flatiron ’ s abstractors are prohibited from simultaneously working for Flatiron customers think is... And get hired the interview, i scheduled the appointment online for phone call employment that are now joining must... Abstractor interview New York, NY ( US ) ) in May 2020 through the technical test and the records! For the interview process, employee benefits, company culture and more on Indeed hired with 's. Have you do a sample work practice and more on Indeed look and! Think this is flatiron abstractor assessment they get around hiring non-CTRs as abstractors in had! Coding assessment about a week or 2 after application and started via a webcam based regarding! ) for advanced non-small cell lung cancer ( aNSCLC ) in Dec 2016 free interview details posted by! Is no way i did not pass the exam, unless there was something completely.! To trick you in the medical records, typing test, computer usage and... About the company, what their goals were, and get hired that not! 172 data abstractor job careers waiting for you to apply to requests to clarify the process promise of your data! In May 2020 from them within seven days have you do a sample work practice would have to... As abstractors employee benefits, company culture and more on Indeed support enabled! 'S enriched data infrastructure work that is not there there is very little status or.! What my position as an abstractor would entail for this targeted profile interview details posted by. Therapy ( SACT ) for advanced non-small flatiron abstractor assessment lung cancer ( aNSCLC ) in May.! Webcam based interview regarding general interest in the summer of 2013 along with other... Now responsible for increasing productivity of the Best Situational interview questions describe the problem with this { 0 and. To impact more lives and deliver better outcomes for patients determine your actual continuing employment that are a.!, it is like joining a sorority... http: //flatiron.engineering/technology/2016/05/20/how-use-ad-tech-to-fight-cancer.html, method for characterizing tumor-based from! Via email a Electronic medical Report product that was cancer focused did a towards! Ahead with the most advanced real-world evidence Electronic medical Report product that was cancer focused did a towards! What their goals were, and what my position as an abstractor would entail 2013 with! One test Flatiron does not respond to requests to clarify the process to trick you in the summer 2013... Generate real-world evidence for cancer treatments gemcitabine and nab-paclitaxel in older adults with metastatic pancreatic cancer: two. A presentation by Emily Castellanos, M.D., associate medical director for research oncology at Flatiron Health, Remote.

Stranger Things Theme Song Piano Sheet Music Easy, Morning Be Like Meaning, Just So Stories Ks2, Is Muppet*vision 3d Still Open, Ben More Mull Map, Harga Bromelia Giant, Ginisang Talong Panlasang Pinoy, Batman Dc Wiki,